May 26, 2023
Stop too soon and you lose whatever might have been gained by adding to exposure; hoping not to sacrifice gains and exhaust your sector optimism
My interpretation of the morning’s numbers is written to be informative; it’s built on what happened or will happen behind the headline today, not tomorrow or yesterday.
Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investors! Never leave an investor uninformed!
8:00 a.m. edition
The week and month of May trading sessions end – TGIF and holiday weekend
May 27, 2023
LPS (loss-per-share) releases will present challenges to share pricing with outcomes included
35 reported to date with one 1 net income (VYGR) ... <read more>
Mesoblast (MESO) 3/25 - Friday
May 27, 2023
Stay “frosty,” debt ceiling negotiations have weighed on market sentiment this week; what about next week if NO deal? I am concerned Dems reuse to budge with a lack of accord!
If you’re looking for sector intel, ideas and facts or Insight in a volatile climate, RMi defines the extenuating factors of share pricing.
Subscription is coming, it is not conscription but, an offer to join our collective of like-minded investors! Join me … in the NO spin zone.
If you want facts to expose share pricing facts to save your portfolio for deliberate decisions, bookmark this site!
Week in review and what a month it has been <see May's breakdown>
May 27, 2023
LPS (loss-per-share) releases will present challenges to share pricing with outcomes included 35 reported to date with one 1 net income (VYGR) ... <read more> Mesoblast (MESO) 3/25 - Friday
May 15, 2023
QURE (+$0.11) will sell a part of the royalty rights for the world's most expensive treatment Hemgenix to HealthCare Royalty and Sagard Healthcare.
April 10, 2023
The cell and gene therapy sector fluctuates in revenues, collaboration, regulatory submissions and expenses, but the changes may alarm investors who prefer to see expectation and consensus stability and share pricing growth. Stock pricing rises or falls before and after an earnings announcement, depending on whether the earnings meet or fall short of expectations. To date … 31 of 35 (adding BLUE, BCLI, ADVM OTCQB: BSTG)
May 27, 2023
RegMed Investors (RMi) Research Note: Q1/23 earnings reporting dates, net losses, cash positions and runway outcomes
May 25, 2023
RegMed Investors’ (RMi) closing bell: another breakdown in sector’s share pricing
May 25, 2023
RegMed Investors’ (RMi) pre-open: what’s the plan?
May 24, 2023
RegMed Investors’ (RMi) closing bell: sector share pricing rolls downhill
May 24, 2023
RegMed Investors’ (RMi) pre-open: debt ceiling talks drag-on after breakdown
May 23, 2023
RegMed Investors’ (RMi) closing bell: sector is affected by debt ceiling “talks” insinuating a Biden default
© 2023 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
